nach oben

Canadian Journal of Anesthesia/Journal canadien d'anesthésie

Erschienen in:

01.03.2010 | Case Reports/Case Series

Anesthesia and myotonic dystrophy type 2: a case series

verfasst von: Toby N. Weingarten, MD, Ryan E. Hofer, MMS, Margherita Milone, MD, PhD, Juraj Sprung, MD, PhD

Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Myotonic dystrophy type 2 (DM2) is a genetically distinct disorder that shares some phenotypical features of myotonic dystrophy type 1 (DM1). However, anesthetic management of patients with DM2 has not been described. The purpose of this study is to report the anesthetic management of a series of patients with DM2 and to describe their response to anesthesia.

Methods

We performed a computerized search of the Mayo Clinic medical records database looking for patients with DM2 who underwent general anesthesia. The medical records were reviewed for anesthetic technique, medications used, and postoperative complications.

Results

We identified 19 patients with DM2 who underwent 39 general anesthetics, 17 monitored anesthetic care cases, and two regional anesthetics. The patients exhibited normal responses to succinylcholine, nondepolarizing neuromuscular blockers, neostigmine, induction agents, and volatile anesthetics. Serious postoperative complications related to DM2 did not occur.

Conclusion

In our series, patients with DM2 tolerated commonly used anesthetics without obvious complications, and they exhibited normal responses to muscle relaxants. These observations suggest that these medications may be used safely in patients with DM2.

Finsterer J. Myotonic dystrophy type 2. Eur J Neurol 2002; 9: 441–7.CrossRefPubMed

Day JW, Ricker K, Jacobsen JF, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60: 657–64.CrossRefPubMed

Buzello W, Krieg N, Schlickewei A. Hazards of neostigmine in patients with neuromuscular disorders. Report of two cases. Br J Anaesth 1982; 54: 529–34.CrossRefPubMed

Ranum LP, Rasmussen PF, Benzow KA, Koob MD, Day JW. Genetic mapping of a second myotonic dystrophy locus. Nat Genet 1998; 19: 196–8.CrossRefPubMed

Ricker K. Myotonic dystrophy and proximal myotonic myophathy. J Neurol 1999; 246: 334–8.CrossRefPubMed

Udd B, Krahe R, Wallgren-Pettersson C, Falck B, Kalimo H. Proximal myotonic dystrophy–a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord 1997; 7: 217–28.CrossRefPubMed

Thiel RE. The myotonic response to suxamethonium. Br J Anaesth 1967; 39: 815–21.CrossRefPubMed

Orndahl G. Myotonic human musculature: stimulation with depolarizing agents. I. Mechanical registration of the effects of acetylcholine and choline. Acta Med Scand 1962; 172: 739–51.PubMed

Orndahl G. Myotonic human musculature: stimulation with depolarizing agents. II. A clinico-pharmacological study. Acta Med Scand 1962; 172: 753–65.PubMed

10.

Orndahl G, Stenberg K. Myotonic human musculature: stimulation with depolarizing agents. Mechanical registration of the effects of succinyldicholine, succinylmonocholine and decamethonium. Acta Med Scand Suppl 1962; 389: 3–29.PubMed

11.

Dundee JW. Thiopentone in dystrophia myotonia. Curr Res Anesth Analg 1952; 31: 257–62.PubMed

12.

Speedy H. Exaggerated physiological responses to propofol in myotonic dystrophy. Br J Anaesth 1990; 64: 110–2.CrossRefPubMed

13.

White DA, Smyth DG. Exaggerated physiological responses to propofol in myotonic dystrophy. Br J Anaesth 1990; 64: 758–9.CrossRefPubMed

14.

Aldridge LM. Anaesthetic problems in myotonic dystrophy. A case report and review of the Aberdeen experience comprising 48 general anaesthetics in a further 16 patients. Br J Anaesth 1985; 57: 1119–30.CrossRefPubMed

15.

Liquori CL, Ricker K, Moseley ML, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293: 864–7.CrossRefPubMed

16.

Savkur RS, Philips AV, Cooper TA, et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet 2004; 74: 1309–13.CrossRefPubMed

17.

Wahbi K, Meune C, Bassez G, et al. Left ventricular non-compaction in a patient with myotonic dystrophy type 2. Neuromuscul Disord 2008; 18: 331–3.CrossRefPubMed

18.

Groh WJ, Groh MR, Saha C, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med 2008; 358: 2688–97.CrossRefPubMed

19.

Schoser BG, Ricker K, Schneider-Gold C, et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004; 63: 2402–4.PubMed

20.

Schneider-Gold C, Beer M, Kostler H, et al. Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): A quantitative 31P-MRS and MRI study. Muscle Nerve 2004; 30: 636–44.CrossRefPubMed

21.

Flachenecker P, Schneider C, Cursiefen S, Ricker K, Toyka KV, Reiners K. Assessment of cardiovascular autonomic function in myotonic dystrophy type 2 (DM2/PROMM). Neuromuscul Disord 2003; 13: 289–93.CrossRefPubMed

22.

Tieleman AA, van Vliet J, Jansen JB, van der Kooi AJ, Borm GF, van Engelen BGM. Gastrointestinal involvement is frequent in myotonic dystrophy type 2. Neuromuscul Disord 2008; 18: 646–9.CrossRefPubMed

23.

Auvinen S, Suominen T, Hannonen P, Bachinski LL, Krahe R, Udd B. Myotonic dystrophy type 2 found in two of sixty-three persons diagnosed as having fibromyalgia. Arthritis Rheum 2008; 58: 3627–31.CrossRefPubMed

24.

Rudnik-Schoneborn S, Schneider-Gold C, Raabe U, Kress W, Zerres K, Schoser BG. Outcome and effect of pregnancy in myotonic dystrophy type 2. Neurology 2006; 66: 579–80.CrossRefPubMed

25.

Modoni A, Silvestri G, Pomponi MG, Mangiola F, Tonali PA, Marra C. Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 2004; 61: 1943–7.CrossRefPubMed

26.

Gaul C, Schmidt T, Windisch G, et al. Subtle cognitive dysfunction in adult onset myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 2006; 67: 350–2.CrossRefPubMed

27.

Sansone V, Gandossini S, Cotelli M, Calabria M, Zanetti O, Meola G. Cognitive impairment in adult myotonic dystrophies: a longitudinal study. Neurol Sci 2007; 28: 9–15.CrossRefPubMed

28.

Moxley RT 3rd, Meola G, Udd B, Ricker K. Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October, 2000, Loosdrecht, The Netherlands. Neuromuscul Disord 2002; 12: 306–17.

29.

Mathieu J, Allard P, Potvin L, Prevost C, Begin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 1999; 52: 1658–62.PubMed

30.

Meola G, Sansone V, Marinou K, et al. Proximal myotonic myopathy: a syndrome with a favourable prognosis? J Neurol Sci 2002; 193: 89–96.CrossRefPubMed

31.

von zur Muhlen F, Klass C, Kreuzer H, Mall G, Giese A, Reimers CD. Cardiac involvement in proximal myotonic myopathy. Heart 1998; 79: 619–21.

32.

Tieleman AA, Knuijt S, van Vliet J, de Swart BJ, Ensink R, van Engelen BG. Dysphagia is present but mild in myotonic dystrophy type 2. Neuromuscul Disord 2009; 19: 196–8.CrossRefPubMed

33.

Milone M, Batish SD, Daube JR. Myotonic dystrophy type 2 with focal asymmetric muscle weakness and no electrical myotonia. Muscle Nerve 2009; 39: 383–5.CrossRefPubMed

34.

Young N, Milone M, Daube JR. Absent or unrecognized electromyographic myotonia in myotonic dystrophy type 2. Neurology 2009; 72 Suppl 3: A823.

Titel: Anesthesia and myotonic dystrophy type 2: a case series
verfasst von: Toby N. Weingarten, MD
Ryan E. Hofer, MMS
Margherita Milone, MD, PhD
Juraj Sprung, MD, PhD
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Ausgabe 3/2010
Print ISSN: 0832-610X
Elektronische ISSN: 1496-8975
DOI: https://doi.org/10.1007/s12630-009-9244-1

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Anesthesia and myotonic dystrophy type 2: a case series